ApoGen Biotechnologies, Inc. — Form D/A
ApoGen Biotechnologies, Inc. of SEATTLE, WA, a company, filed a Form D amendment with the SEC on 2018-08-24. The offering totals $7.6M, of which $7.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2018-08-24
- Form: D/A
- Accession: 0001691479-18-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $7.6M
- Amount sold: $7.6M
- Investors: 24
- Date of first sale: 2016-11-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-275911
Issuer
- Name: ApoGen Biotechnologies, Inc.
- CIK: 0001691479
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2014
- Address: 1616 EASTLAKE AVE E., SEATTLE, WA, 98102
- Phone: 206-957-7300
Officers, directors & promoters (17)
| Name | Role | Location |
|---|
| M. Johnston Erwin | Director | New York, NY |
| Steve Gillis | Director | New York, NY |
| Keno Gutierrez | Director | Dover, DE |
| THONG LE | Director | Seattle, WA |
| Joel Johnston Marcus | Director | Seattle, WA |
| John Johnston Santini | Director | Seattle, WA |
| James Johnston Sullivan | Director | Seattle, WA |
| Asish Xavier | Director | South San Francisco, CA |
| Ian AW Howes | Executive Officer | Seattle, WA |
| THONG LE | Executive Officer | Seattle, WA |
| James Sullivan | Director | San Jose, CA |
| John Santini | Director | Minneapolis, MN |
| LINDSAY RAYLE | Executive Officer | New York, NY |
| Joel Marcus | Director | South San Francisco, CA |
| David Schubert | Executive Officer | New York, NY |
| Johnston Erwin | Director | Indianapolis, IN |
| David McElligott | Executive Officer | New York, NY |
Other filings by this issuer (1)
More